Healthcare Industry News: HYLENEX
News Release - July 26, 2006
Halozyme Therapeutics Names Robert Little Chief Commercial OfficerInnovation-Driven Company Adds Commercial Expertise as First Products are Marketed
SAN DIEGO, July 26 (HSMN NewsFeed) -- Halozyme Therapeutics, Inc. (Amex: HTI ), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that Robert Little has been named Vice President and Chief Commercial Officer. Mr. Little will help drive all of the Company's commercial activities for the FDA approved Cumulase® and HYLENEX products, as well as prepare the markets for Enhanze® Technology. He will build upon and manage Halozyme's capabilities in areas such as sales and marketing, business development, alliance management, and portfolio management. Mr. Little will report directly to Jonathan Lim, MD, Halozyme's President and CEO.
Mr. Little was previously Senior Vice President, Commercial Operations at Neurocrine Biosciences, where he was responsible for building and managing the Company's commercial organization. During his tenure, Mr. Little implemented a 200-person CNS sales force that successfully co-detailed Zoloft® with Pfizer, as well as a marketing team that provided commercial direction to the companies' new products in both research and development.
From 1985 to 2003, Mr. Little was at Pharmacia, Inc. where he was Group Vice President, Diversified Products. He managed Pharmacia's Global Diversified Products business, as well as formed a new business unit merging the pricing, reimbursement, and health outcomes groups to focus on current industry issues of pricing and drug values. From 1999 to 2001, Mr. Little was Group Vice President, Specialty Products, the worldwide head of a $2.5 billion, global business focused on Specialty Markets. He had full global sales and P&L responsibility, and grew core businesses by 30 percent in 1999/2000 (both Sales and EBIT).
Mr. Little also held a number of positions within Pharmacia, including heading their country operations in both Italy and Canada. Mr. Little earned his degree in economics and finance from the West London Business School.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity. The company has received FDA approval for two products: Cumulase®, the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and HYLENEX for use as an adjuvant to increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the progress towards commercializing its first products) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-KSB, 10-Q and other filings with the Securities and Exchange Commission.
Source: Halozyme Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.